endTB clinical trial offers new shortened drug regimens to treat multidrug-resistant TB

Governments must immediately implement latest WHO guidelines to stop children dying from TB

Recent price reductions to WHO-recommended TB tests and treatment should enable more countries to make these vital medical tools available

Governments must now turn words on paper into practice and take the necessary steps to save more lives of people with TB

Cepheid and Danaher have just announced that they are reducing the price of the Xpert MTB/RIF test by 20% in high-TB-burden countries, from US$9.98 to $7.97 per test. This reduction is a significant step, considering the corporations ...

Access to TB drug bedaquiline, a backbone medicine for drug-resistant TB treatment regimens, remains out of reach for too many

MSF called on governments and donors to speed up access to diagnostic tests, and shorter, safer and more effective treatments, for DR-TB.

Findings that prompted WHO to update global DR-TB treatment guidelines now published in the New England Journal of Medicine, show that a much shorter treatment regimen for drug-resistant TB is safer and cured almost 90 percent of ...

Due to the high number of countries currently experiencing cholera outbreaks and a shortage of oral cholera vaccine, the International Coordinating Group (ICG) announced today that it will temporarily suspend the standard two-dose ...

Next week the Indian government is expected to decide whether it is willing to override patents on two critical tuberculosis (TB) drugs following a court petition filed at the Mumbai High Court by two survivors of TB and activists. MSF ...

MSF calls on governments and donors to step up and speed up TB testing and treatment

The World Health Organization (WHO) released today the 2020 edition of its Global Tuberculosis (TB) Report. The report, which WHO releases annually, features data on disease trends and the response to the epidemic in 198 countries and ...

MSF protested in front of the New York Stock Exchange in New York today, demanding the pharmaceutical corporation Johnson & Johnson make the tuberculosis drug bedaquiline available for all people with drug-resistant TB or no more than ...

Newer medicines for DR-TB are desperately needed, but barriers to access, including high prices, keep them out of reach for most people around the world.

Approved as part of a novel shorter treatment regimen, the new drug pretomanid could be a lifesaver for people with XDR-TB, but MSF warns it must be made affordable to make a real difference.

Médecins Sans Frontières (MSF) is supporting a patent challenge filed in India this week by two tuberculosis survivors, to prevent pharmaceutical corporation Johnson & Johnson (J&J) from extending its monopoly on the tuberculosis drug ...

MSF welcomes new WHO treatment guidelines that recommend drug-resistant tuberculosis be treated with oral drugs only, including newer, more potent drugs with fewer side effects, such as bedaquiline.